In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Dexcom (DXCM – Research Report), with a price target of ...

DexCom Inc. closed 51.60% short of its 52-week high of $139.24, which the company achieved on April 25th.

BTIG lowered the firm’s price target on DexCom (DXCM) to $107 from $120 and keeps a Buy rating on the shares as part of a broader research note ...

DXCM secures FDA clearance for its G7 15-Day CGM, the longest-lasting and most accurate wearable, enhancing user convenience ...

The global demographic shift is reshaping healthcare demand, driving long-term investment in pharmaceuticals, medical devices ...

Sands Capital, an investment management company, released its “Sands Capital Select Growth Fund” Q4 2024 investor letter. A ...

Stock futures dipped on Thursday as investors weighed President Trump’s 90-day tariff reprieve for select countries, which ...

In addition to Citi, Dexcom also received a Buy from Raymond James’s Jayson Bedford in a report issued yesterday. However, today, Barclays maintained a Hold rating on Dexcom (NASDAQ: DXCM). The ...

Fintel reports that on April 10, 2025, Mizuho initiated coverage of DexCom (NasdaqGS:DXCM) with a Outperform recommendation. Analyst Price Forecast Suggests 57.82% Upside As of April 1, 2025, the ...

Dexcom advanced the launch of Stelo, its over-the-counter product for non-insulin type 2 diabetes, pre-diabetes, and ...

CGM approved by FDA for adults with diabetes; U.S. launch set for late 2025 with extended wear and advanced tracking features ...